(USPH) US Physicalrapy - Ratings and Ratios
Physical Therapy, Industrial Prevention, Rehabilitation, Ergonomic Services
Dividends
| Dividend Yield | 2.40% |
| Yield on Cost 5y | 1.81% |
| Yield CAGR 5y | 53.14% |
| Payout Consistency | 92.0% |
| Payout Ratio | 73.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 30.4% |
| Value at Risk 5%th | 46.1% |
| Relative Tail Risk | -8.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.72 |
| Alpha | -34.94 |
| CAGR/Max DD | -0.07 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.575 |
| Beta | 0.778 |
| Beta Downside | 0.790 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.32% |
| Mean DD | 21.58% |
| Median DD | 23.64% |
Description: USPH US Physicalrapy November 12, 2025
U.S. Physical Therapy, Inc. (NYSE: USPH) runs a network of outpatient physical-therapy clinics and delivers industrial injury-prevention services. Its two operating segments-Physical Therapy Operations and Industrial Injury Prevention Services-cover pre- and post-operative orthopedic care, sports-injury rehab, neurological therapy, and workplace-focused programs such as on-site ergonomics, functional capacity evaluations, and performance-optimization for Fortune 500 firms, insurers and contractors. The company, founded in 1990 and headquartered in Houston, Texas, is classified under the Health Care Facilities sub-industry.
Key metrics that shape USPH’s outlook include a FY 2023 revenue of roughly $420 million, representing a 9 % year-over-year increase driven largely by same-store growth and expanding corporate contracts. The outpatient physical-therapy market is projected to expand at a CAGR of ~5 % through 2028, buoyed by an aging U.S. population and rising prevalence of musculoskeletal disorders. However, the business remains sensitive to Medicare reimbursement policy shifts and a persistent therapist labor shortage that can constrain clinic capacity.
For a deeper, data-driven assessment of USPH’s valuation and competitive positioning, consider exploring the analytics platform ValueRay, which aggregates real-time financial and operational benchmarks for health-care service firms.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (33.4m TTM) > 0 and > 6% of Revenue (6% = 39.7m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -2.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.53% (prev 13.87%; Δ -10.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 69.5m > Net Income 33.4m (YES >=105%, WARN >=100%) |
| Net Debt (277.3m) to EBITDA (113.8m) ratio: 2.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.2m) change vs 12m ago 0.84% (target <= -2.0% for YES) |
| Gross Margin 21.67% (prev 18.88%; Δ 2.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.42% (prev 62.74%; Δ -3.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.86 (EBITDA TTM 113.8m / Interest Expense TTM 9.16m) >= 6 (WARN >= 3) |
Altman Z'' 1.93
| (A) 0.02 = (Total Current Assets 138.4m - Total Current Liabilities 115.1m) / Total Assets 1.20b |
| (B) 0.20 = Retained Earnings (Balance) 237.3m / Total Assets 1.20b |
| (C) 0.08 = EBIT TTM 90.3m / Avg Total Assets 1.11b |
| (D) 0.58 = Book Value of Equity 238.4m / Total Liabilities 413.8m |
| Total Rating: 1.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.69
| 1. Piotroski 5.50pt |
| 2. FCF Yield 4.16% |
| 3. FCF Margin 8.61% |
| 4. Debt/Equity 0.61 |
| 5. Debt/Ebitda 2.44 |
| 6. ROIC - WACC (= 3.54)% |
| 7. RoE 6.71% |
| 8. Rev. Trend 88.00% |
| 9. EPS Trend -21.95% |
What is the price of USPH shares?
Over the past week, the price has changed by +1.60%, over one month by -14.25%, over three months by -11.84% and over the past year by -21.31%.
Is USPH a buy, sell or hold?
- Strong Buy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the USPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 106.8 | 42.4% |
| Analysts Target Price | 106.8 | 42.4% |
| ValueRay Target Price | 76.2 | 1.5% |
USPH Fundamental Data Overview November 25, 2025
P/E Trailing = 30.2236
P/E Forward = 25.8398
P/S = 1.4503
P/B = 2.1627
P/EG = 2.5859
Beta = 1.304
Revenue TTM = 661.2m USD
EBIT TTM = 90.3m USD
EBITDA TTM = 113.8m USD
Long Term Debt = 151.5m USD (from longTermDebt, last quarter)
Short Term Debt = 50.8m USD (from shortTermDebt, last quarter)
Debt = 308.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 277.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.37b USD (1.09b + Debt 308.4m - CCE 31.1m)
Interest Coverage Ratio = 9.86 (Ebit TTM 90.3m / Interest Expense TTM 9.16m)
FCF Yield = 4.16% (FCF TTM 56.9m / Enterprise Value 1.37b)
FCF Margin = 8.61% (FCF TTM 56.9m / Revenue TTM 661.2m)
Net Margin = 5.05% (Net Income TTM 33.4m / Revenue TTM 661.2m)
Gross Margin = 21.67% ((Revenue TTM 661.2m - Cost of Revenue TTM 517.9m) / Revenue TTM)
Gross Margin QoQ = 22.48% (prev 25.35%)
Tobins Q-Ratio = 1.14 (Enterprise Value 1.37b / Total Assets 1.20b)
Interest Expense / Debt = 0.78% (Interest Expense 2.41m / Debt 308.4m)
Taxrate = 22.88% (5.23m / 22.9m)
NOPAT = 69.7m (EBIT 90.3m * (1 - 22.88%))
Current Ratio = 1.20 (Total Current Assets 138.4m / Total Current Liabilities 115.1m)
Debt / Equity = 0.61 (Debt 308.4m / totalStockholderEquity, last quarter 503.6m)
Debt / EBITDA = 2.44 (Net Debt 277.3m / EBITDA 113.8m)
Debt / FCF = 4.87 (Net Debt 277.3m / FCF TTM 56.9m)
Total Stockholder Equity = 497.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.79% (Net Income 33.4m / Total Assets 1.20b)
RoE = 6.71% (Net Income TTM 33.4m / Total Stockholder Equity 497.6m)
RoCE = 13.92% (EBIT 90.3m / Capital Employed (Equity 497.6m + L.T.Debt 151.5m))
RoIC = 10.59% (NOPAT 69.7m / Invested Capital 657.7m)
WACC = 7.05% (E(1.09b)/V(1.40b) * Re(8.88%) + D(308.4m)/V(1.40b) * Rd(0.78%) * (1-Tc(0.23)))
Discount Rate = 8.88% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.72%
[DCF Debug] Terminal Value 75.05% ; FCFE base≈63.6m ; Y1≈62.6m ; Y5≈64.5m
Fair Price DCF = 64.72 (DCF Value 984.0m / Shares Outstanding 15.2m; 5y FCF grow -2.35% → 3.0% )
EPS Correlation: -21.95 | EPS CAGR: -2.29% | SUE: -0.11 | # QB: 0
Revenue Correlation: 88.00 | Revenue CAGR: 6.43% | SUE: -2.29 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=-0.037 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=3.02 | Chg30d=-0.026 | Revisions Net=+0 | Growth EPS=+14.9% | Growth Revenue=+6.2%
Additional Sources for USPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle